Drug Profile
NOV 12
Alternative Names: NOV-12Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator MorphoSys; Novartis
- Class Antibodies; Antithrombotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for phase-I development in Thrombosis(Prevention) in Germany
- 28 Aug 2019 No recent reports of development identified for phase-I development in Thrombosis(Prevention) in Switzerland
- 04 Jul 2016 Phase-I clinical trials in Thrombosis (Prevention) in Switzerland and Germany (unspecified route)